|
|
Blood, 1 December 2003, Vol. 102, No. 12, pp. 3906-3911.
Prepublished online as a Blood First Edition Paper on June 19, 2003; DOI 10.1182/blood-2003-02-0630.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Rituximab in relapsed or refractory hairy cell leukemia
Deborah A. Thomas,
Susan O'Brien,
Carlos Bueso-Ramos,
Stefan Faderl,
Michael J. Keating,
Francis J. Giles,
Jorge Cortes, and
Hagop M. Kantarjian
From the Departments of Leukemia and Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston.
The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly for a total of 8 planned doses. An additional 4 doses could be administered to responders who had not achieved complete response (CR). The overall response rate was 80%. Eight patients (53%) achieved CR, 2 (13%) attained CR by hematologic parameters with residual marrow disease (1% to 5% marrow hairy cells), and 2 (13%) had a partial response. Of the 12 responders followed for a median of 32 months (range, 8 to 45+ months), 5 patients (42%) had progression of disease 8, 12, 18, 23, and 39 months from the start of therapy. Three patients failed to respond (after 4, 6, or 8 doses). Reductions in serum interleukin-2 receptor (sIL-2R) levels correlated with response. Toxicity was minimal, and no infectious episodes were observed. Rituximab has significant activity and minimal toxicity in HCL and warrants further study. Rituximab should be explored further in HCL with regard to eradication of minimal residual disease and in combination with nucleoside analogs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. J. Kreitman, M. Stetler-Stevenson, I. Margulies, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
J. Clin. Oncol.,
June 20, 2009;
27(18):
2983 - 2990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas, S. O'Brien, J. L. Jorgensen, J. Cortes, S. Faderl, G. Garcia-Manero, S. Verstovsek, C. Koller, S. Pierce, Y. Huh, et al.
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Blood,
June 18, 2009;
113(25):
6330 - 6337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zenhausern, M. Simcock, A. Gratwohl, U. Hess, M. Bargetzi, A. Tobler, and on behalf of the Swiss Group for Clinical Cancer R
Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)
Haematologica,
September 1, 2008;
93(9):
1426 - 1428.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Golomb
Hairy Cell Leukemia: Treatment Successes in the Past 25 Years
J. Clin. Oncol.,
June 1, 2008;
26(16):
2607 - 2609.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cittera, M. Leidi, C. Buracchi, F. Pasqualini, S. Sozzani, A. Vecchi, J. D. Waterfield, M. Introna, and J. Golay
The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab
J. Immunol.,
May 15, 2007;
178(10):
6616 - 6623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Wanko and C. de Castro
Hairy Cell Leukemia: An Elusive but Treatable Disease
Oncologist,
July 1, 2006;
11(7):
780 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi, J. L. Jorgensen, S. M. O'Brien, S. Verstovsek, C. A. Koller, S. Faderl, F. J. Giles, A. Ferrajoli, W. G. Wierda, S. Odinga, et al.
Eradication of minimal residual disease in hairy cell leukemia
Blood,
June 15, 2006;
107(12):
4658 - 4662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Arons, I. Margulies, L. Sorbara, M. Raffeld, M. Stetler-Stevenson, I. Pastan, and R. J. Kreitman
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
Clin. Cancer Res.,
May 1, 2006;
12(9):
2804 - 2811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
J. Clin. Oncol.,
September 20, 2005;
23(27):
6719 - 6729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Chadha, A. W. Rademaker, P. Mendiratta, B. Kim, D. M. Evanchuk, D. Hakimian, L. C. Peterson, and M. S. Tallman
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience
Blood,
July 1, 2005;
106(1):
241 - 246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al.
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Blood,
September 15, 2004;
104(6):
1793 - 1800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
